The 2026 Healthtech Messaging Index
Holmusk
holmusk.com·scored September 1, 2026
20/38
Invisible
The page is doing some work, but the story isn't landing fast enough. Buyers and AI are both left guessing what makes Holmusk different.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for real-world evidence data and analytics for neuropsychiatry and behavioral health, it named:
Buyer we put in the prompt: Director of Real-World Evidence or Medical Affairs at a life sciences / pharmaceutical company developing neuropsychiatry drugs, or a behavioral health researcher at an academic or payer institution. Both the buyer and the category were inferred from Holmusk’s homepage alone. The model had no web access.
Holmusk was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI named you when asked who it recommends for "real-world evidence data and analytics for neuropsychiatry and behavioral health", and described you accurately: "Holmusk is a data and analytics company focused specifically on behavioral health and neuropsychiatry, known for their NeuroBlu database of real-world patient data used by pharma and researchers to generate evidence in mental health conditions.". Your positioning is landing with the machines.
Overall assessment
Holmusk's biggest strength is its concrete, specific data scale (46.5M patients, 50-state coverage, 20+ years, named proprietary products) which gives it genuine entity distinctiveness and quotable proof points no generic competitor could match. Its biggest gap is a complete absence of social proof ... not a single named customer, testimonial, or case study appears despite targeting five distinct buyer segments ... which means all those impressive numbers land with no third-party validation to make them believable. The page also fails to name the cost of inaction or paint a vivid promised land, leaving buyers with capability inventory rather than a reason to act now.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
07Cost of Inaction
“No mention of consequences of not acting ... no lost deals, failed trials, wasted budgets, or competitive risk named anywhere on the page.”
The page never names what happens to a researcher or pharma team that continues without Holmusk's data ... there is zero cost-of-inaction framing.
All 19 signals, scored 0 to 2.
Total 20/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Creating the standard for neuropsychiatry with best-in-class real-world evidence”
The vertical (neuropsychiatry) and mission are clear in 7 seconds, but who the buyer is and what specific problem it solves for them is not immediately obvious ... 'creating the standard' is aspirational jargon, not a problem-solution statement a caveman would grasp.
- 1
02Rebellion / Movement
“There is currently no standardized way to measure symptoms or quality of care for neuropsychiatric conditions”
There is a named status quo problem (lack of standardization), but no named enemy, no named incumbent approach being rejected, and no missionary 'against' framing ... it reads as a market observation, not a rebellion.
- 2
03Owned Language & Category
“NeuroBlu Database...NeuroBlu Analytics...first-in-kind natural language processing models developed specifically for behavioral health”
Holmusk owns clearly named proprietary terms ... NeuroBlu Data, NeuroBlu Analytics, NeuroBlu Database ... and claims a 'first-in-kind' NLP category specifically for neuropsychiatry that an AI could cite back distinctively.
- 1
04ICP Clarity
“Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges”
Three buyer personas are named (researcher, clinician, payer) but company size, stage, geography, and specific roles are never specified, making it hard for any single visitor to immediately confirm they're the intended buyer.
- 1
05Problem Leadership
“Neuropsychiatry needs better evidence to drive decision-making. There is currently no standardized way to measure symptoms or quality of care”
The page does open with a problem statement before the solution, but it is framed in clinical/industry language rather than in the buyer's operational pain language (e.g., failed trials, wasted spend, slow approvals).
- 1
06Solution Clarity
“We've built the field's largest, most robust source of clinical data for real-world data and a uniquely powerful evidence engine”
A visitor can roughly understand Holmusk provides neuropsychiatry real-world data and analytics, but the one-sentence explanation is muddied by redundant phrasing ('real-world data for real-world data') and multiple overlapping product names.
- 0
07Cost of Inactionweakest
“No mention of consequences of not acting ... no lost deals, failed trials, wasted budgets, or competitive risk named anywhere on the page.”
The page never names what happens to a researcher or pharma team that continues without Holmusk's data ... there is zero cost-of-inaction framing.
- 1
08Promised Land
“generate impactful evidence...improved patient outcomes...guide decisions for successful treatment development, efficient care delivery”
An 'after' state is sketched (better evidence, better outcomes) but it is generic and lacks specificity ... no concrete timeframes, no quantified improvements in trial success rates or care metrics that would make the promised land vivid.
Trust Signal
4 signals
- 2
09Proof & Evidence
“1,300,000+ patients...30+ geographically-diverse health systems...20+ years of longitudinal data...46,500,000 Patients...50 State coverage”
The page is dense with specific, concrete numbers across conditions and database scale, providing genuine quantitative evidence rather than adjective-only claims.
- 0
10Social Proof
“No customer logos, named testimonials, named case studies, or video stories found anywhere on the page.”
Despite listing five buyer segments (life sciences, providers, payers, government, academia), not a single named customer, quote with attribution, or case study appears on the page.
- 1
11Authority & Credibility
“first-in-kind natural language processing models developed specifically for behavioral health”
The NLP 'first-in-kind' claim and clinical expertise positioning hint at authority, but no founder credentials, published research citations, awards, or named experts are surfaced on the homepage to demonstrate it.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, or 'do nothing' option anywhere on the page.”
The page never acknowledges that buyers could use general claims databases, competitors like Komodo or IQVIA, or simply conduct traditional RCTs ... alternatives are completely ignored.
AI Signal
6 signals
- 1
13Customer Focus
“Our solutions have been leveraged by a range of stakeholders who share our vision that better evidence can vastly improve neuropsychiatry”
The page tilts toward Holmusk's capabilities and data assets rather than the customer's transformation ... the customer is referenced but the protagonist throughout is Holmusk and its platform.
- 2
14AI-Parmesan Index
“first-in-kind natural language processing models developed specifically for behavioral health...extract important information from unstructured clinical notes”
AI/NLP claims are mechanistic and specific ... describing exactly what the models do (extract from unstructured clinical notes, transform into standardized measures) rather than vague 'AI-powered' sprinkling.
- 1
15LLM Quotability
“The NeuroBlu Database enables researchers to build robust patient cohorts and conduct studies at an unprecedented level of granularity”
There are quotable sentences but they lean on superlatives ('unprecedented') rather than clean, declarative, citation-ready facts that an LLM could lift with confidence; numbers and product names are stronger candidates but not packaged as pithy claims.
- 0
16Copyright Freshness
“No visible blog post dates, case study dates, or copyright year found in the scraped content.”
No publication dates on content and no visible copyright year appear in the scraped page, removing all recency signals that AI engines weight.
- 2
17Entity Distinctiveness
“NeuroBlu...field's largest, most robust source of clinical data...first-in-kind natural language processing models developed specifically for behavioral health”
The combination of proprietary product names (NeuroBlu), a specific vertical (neuropsychiatry/behavioral health), NLP models built exclusively for that vertical, and scale metrics makes Holmusk distinctly attributable ... an AI could not confuse this with a general claims database vendor.
- 2
18AI Recommendation Check
“AI described you as: "Holmusk is a data and analytics company focused specifically on behavioral health and neuropsychiatry, known for their NeuroBlu database of real-world patient data used by pharma and researchers to generate evidence in mental health conditions.”
AI named you when asked who it recommends for "real-world evidence data and analytics for neuropsychiatry and behavioral health", and described you accurately: "Holmusk is a data and analytics company focused specifically on behavioral health and neuropsychiatry, known for their NeuroBlu database of real-world patient data used by pharma and researchers to generate evidence in mental health conditions.". Your positioning is landing with the machines.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“GET STARTED / Contact us...Request A Demo...LEARN MORE”
There are multiple CTAs (Get Started, Contact Us, Request a Demo, Learn More) but no numbered process or clear path showing what happens next, and the primary vs. secondary CTA hierarchy is diluted by repetition across the page.
Keep the lead
AI already names Holmusk. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Holmusk the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.